Prostate specific membrane antigen (PSMA) is a type of protein concentrated within the cells of a man’s prostate gland. It is substantially higher in malignant cells, which is why it is used as a “marker” for prostate cancer. PSMA PET/CT is a new type of PET/CT scan that measures prostate specific membrane antigen (PSMA).
PSMA PET/CT is approved for both initial staging of recently diagnosed prostate cancer, as well as the evaluation of possible local recurrence or metastatic disease in patients with previous treatment.
During a PET-CT scan, a special targeted tracer is injected into the body. The tracer binds to active PSMA molecules, enabling our radiologists to visualize the cancer cells.
It is a superior technology for the staging of prostate cancer, with a 92% accuracy rate compared to 65% with conventional imaging. It is also used to help your doctor guide personalized treatment decisions. PSMA PET-CT provides such precise information, that in many cases it can help to increase the number and type of therapies available to treat prostate cancer.